MYL-MNTA partnership includes MNTA’s Orencia FoB plus five undisclosed FoB compounds from MNTA’s pipeline. It excludes the Humira FoB MNTA is developing with BXLT.
MYL-MNTA FoB partnerhsip is fully separate from MYL's FoB partnership with Biocon, which includes FoBs for Herceptin, Neulasta, Avastin, Humira, Enbrel, and insulin analogs (#msg-72421544, #msg-84561737).